Astuprotimut-R

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Astuprotimut-R
Accession Number
DB14926
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Recombinant
Description

Astuprotimut-R is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).

Synonyms
Not Available
External IDs
MAGE-A3
Categories
Not Available
UNII
50I23C5UOR
CAS number
949885-73-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentCancer, Bladder1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Not Yet RecruitingTreatmentMetastatic Melanoma / Squamous Cell Skin Carcinoma1
1Unknown StatusTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
1WithdrawnTreatmentNeuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic1
1, 2Active Not RecruitingTreatmentAdvanced/Metastatic Solid Tumours1
1, 2Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2CompletedTreatmentMalignant Melanoma of Skin / Melanoma (Skin)1
1, 2RecruitingTreatmentBreast Cancer / Cervical Cancers / Esophageal Carcinoma / Melanoma / Melanoma, Malignant / Metastatic Cancer That Express the MAGE-A3-DP4 Antigen / Renal Cancers / Sarcomas / Urothelial Cancer1
1, 2TerminatedTreatmentBreast Cancer / Cancer, Bladder / Cervical Cancers / Esophageal Carcinoma / Melanoma / Melanoma, Malignant / Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen / Metastatic Cancers / Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen / Renal Cancers / Sarcomas / Urothelial Cancer1
1, 2TerminatedTreatmentMelanoma1
1, 2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cancer1
2CompletedTreatmentAdvanced Myeloma / Plasma Cell Myeloma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Extraocular Extension Melanoma / Iris Melanoma / Metastatic Intraocular Melanoma / Mucosal Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IIC Melanoma / Stage IIIA Intraocular Melanoma / Stage IIIA Melanoma / Stage IIIB Intraocular Melanoma / Stage IIIB Melanoma / Stage IIIC Intraocular Melanoma / Stage IIIc Melanoma / Stage IV Intraocular Melanoma / Stage IV Melanoma1
2CompletedTreatmentMelanoma3
2TerminatedTreatmentMelanoma2
2, 3CompletedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:35 / Updated on March 01, 2020 21:58

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates